Drug cocktails for effective treatment of glioblastoma multiforme

Expert Review of Neurotherapeutics

Volumn 8, Issue 4, 2008, Pages 515-517

  Debinski, Waldemar ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; EPHRIN RECEPTOR A2; EXOTOXIN; INTERLEUKIN 13 RECEPTOR ALPHA2; TRANSCRIPTION FACTOR FRA 1;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; EDITORIAL; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOGENICITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL;

EID: 42249089350     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.4.515     Document Type: Editorial

References (20)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
2. Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J. Natl Compr. Canc. Netw. 3, 721-728 (2005).
3. Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest. 20, 801-809 (2002).
4. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells over-express receptor for IL13 and are extremely sensitive to a novel chimeric protein composed of IL13 and Pseudomonas exotoxin. Clin. Cancer Res. 1, 1253-1258 (1995).
5. Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25, 837-844 (2007).
6. Kunwar S, Westphal M, Medhorn M et al. Results from PRECISE: a randomized Phase 3 study in patients with first recurrent GBM comparing Cintredekin Besudotox administered via convection-enhanced delivery with Gliadel wafers. Neuro-oncology 9, 531 (2007). •• As in [5], this study establishes clinical efficacy of a recombinant cytotoxin in patients with glioblastoma multiforme (GBM).
7. Saikali S, Avril T, Collet B et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy. J. Neurooncol. 81, 139-148 (2007).
8. Zhang JG, Eguchi J, Kruse C et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin. Cancer Res. 13, 566-575 (2007). • Demonstrates an interesting profile of antigens found in GBM suitable for targeting using multivalent vaccines.
9. Liu TF, Tatter SB, Willingham MC, Yang MY, Hu J, Frankel A. Growth factor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol. Cancer Ther. 2(8), 783-787 (2003).
10. Wykosky J, Gibo DM, Stanton C, Debinski W. IL-13 Receptor α-2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin. Cancer Res. 14, 199-208 (2008). •• Establishes first ever documented trimolecular signature of GBM.
11. Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlated better with survival than histological classification. Cancer Res. 63, 1602-1607 (2003).
12. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3, 541-551 (2005).
13. Liu F, Park PJ, Lai W et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res. 66, 10815-10823 (2006).
14. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells. Mol. Cancer Ther. 6, 3208-3218 (2007)
15. Liu TF, Willingham MC, Tatter SB et al. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. J. Neurooncol. 65(1), 77-85 (2003).
16. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. Anti-glioblastoma effect of a recombinant bi-specific cytotoxin co-targeting human IL-13 and EGF receptors in a mouse xenograft model. J. Neurooncol. 87(1), 51-61 (2008). • Demonstrates better efficacy of double-targeting of GBM with recombinant cytotoxins.
17. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007).
18. Debinski W, Slagle-Webb B, Achen MG et al. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol. Med. 7, 598-608 (2001).
19. Mischel PS, Cloughesy T. Using molecular information to guide brain tumor therapy. Nat. Clin. Pract. Neurol. 2(5), 232-233 (2006).
20. Debinski W. Personalized, multivalent, and more affordable: the globalization of vaccines. Clin. Cancer Res. 11, 5663-5664 (2005).